



**What if cancer
patients **always**
had treatment
options?**



**Millions of
mutation
profiles**



**Hundreds of
thousands of
drug combos**

**Too much for any doctor, or
team of doctors, to consider**



ROSALIND

Smart data platform that evaluates a tumor's gene mutation profile & **identifies treatments** most likely to **restore normal cell signaling**

Fee for service revenue model

- Physician provides us with gene mutation & expression profile
- We charge \$1,000 for the completed assessment



\$35B

Personalized cancer gene profiling market by 2018*

* Markets and Markets

Available to oncologists today!

The Ask:

~\$2 million USD over 1-2 years to:

- Complete ongoing system validation
- Build out infrastructure and revenue model with cancer centers and payers

Financing best achieved in private company setting

Disclaimer:

- ROSALIND is a patent pending computational research and personalized cancer care tool that continues to undergo development and real world validation.
- ROSALIND is not intended to replace or supersede the assessments or decisions of any experienced physician or group of physicians.
- The ROSALIND information is NOT a prescription for any treatment(s) and in no way obligates any physician or group of physicians to use any part of the information provided in any way.
- The sole purpose of ROSALIND is to provide information only regarding treatment options that might otherwise not have been considered.
- ROSALIND only considers drugs that have been approved for the treatment of cancer.
- ROSALIND should not be used without the express and informed consent of the patient. By using ROSALIND, the physician acknowledges that he or she has obtained this consent.
- ROSALIND does not warrant or guarantee the effectiveness of its informational output to the physician.